| Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED |
2021-02-17 |
| Ginolis–Cellink: investment, 202102– acquisition 100% of Ginolis for €70m with €42m in cash + €28m in shares ANNOUNCED |
2021-02-15 |
| Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact |
2021-02-11 |
| SpyBiotech–Alphabet: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor GV |
2021-02-10 |
| SpyBiotech–Braavos Investment Advisors: investment, 202102 financing round Series A totalling $32.5m incl new + lead investor Braavos |
2021-02-10 |
| SpyBiotech–Oxford Investment Consultants: investment, 202102 financing round Series A totalling $32.5m incl new + co-investor OIC |
2021-02-10 |
| SpyBiotech–SEVERAL: investment, 202102 financing round Series A $32.5m led by new investor Braavos Investment Advisers |
2021-02-10 |
| SpyBiotech–United Kigdom (govt): investment, 202102 financing round Series A totalling $32.5m incl Future Fund converting prior convertible loan |
2021-02-10 |
| SpyBiotech–Univ Oxford: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor Oxford Sciences Innovation |
2021-02-10 |
| Pan Cancer T–Netherlands (govt): grant, 202102 Health~Holland grant for public-private-partnership with Erasmus Medical Center |
2021-02-08 |
| Pan Cancer T–SEVERAL: investment, 202102 seed financing round from Swanbridge Capital + Van Herk Ventures |
2021-02-08 |
| Pan Cancer T–Swanbridge Capital: investment, 202102 seed financing round incl investor Swanbridge Capital |
2021-02-08 |
| Pan Cancer T–Van Herk: investment, 202102 seed financing round incl investor Van Herk Ventures |
2021-02-08 |
| InfanDx–Akampion: public relations, 202102 service existent by Akampion |
2021-02-04 |
| PepGen–Verge Scientific Communications: public relations, 202102 service existent by Verge |
2021-02-04 |
| Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets |
2021-02-04 |
| V-Bio Ventures–SEVERAL: investment, 202102 first closing €78m capital commitments for new V-Bio Ventures Fund 2 |
2021-02-04 |
| Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson |
2021-02-03 |
| Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
| GW Pharmaceuticals–Jazz Pharmaceuticals: investment, 202102– acquisition $7.2b at $220/ADS with $200 in cash + $20 in ordinary shares ANNOUNCED |
2021-02-03 |
| Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy |
2021-02-02 |
| Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD |
2021-01-28 |
| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| BiondVax–SEVERAL: investment, 202101– Pulbic Offering $12m+$1.8m with 2.4m+365k ADSs at $4.95/ADS |
2021-01-28 |
| Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund |
2021-01-28 |
| Lauxera Capital–SEVERAL: investment, 2020–2021 launch of €100m fund incl investors Bpifrance + Covéa + Téthys + CNP et al |
2021-01-27 |
| GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg |
2021-01-26 |
| GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF |
2021-01-26 |
| GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
| GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences |
2021-01-26 |
| GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications |
2021-01-26 |
| Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital |
2021-01-25 |
| Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital |
2021-01-25 |
| CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
| Lift BioSciences–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Omnix Medical–EU (govt): grant, 202101– funding €10.8m under EIC Accelerator Programme to advance antibiotic OMN6 |
2021-01-25 |
| TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund |
2021-01-25 |
| TScan Therapeutics–Pitango: investment, 202101 financing round Series C totalling $100m incl existing investor Pitango HealthTech |
2021-01-25 |
| TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital |
2021-01-25 |
| Servier–MiNA Therapeutics: saRNA therapeutics, 202101– collab research + license option for saRNA therapeutics for neurological diaseses |
2021-01-21 |
| AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones |
2021-01-20 |
| Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq |
2021-01-20 |
| Neurent Medical–Atlantic Bridge: investment, 202101 financing round Series B totalling €21m incl co-lead investor Atlantic Brdige Growth Fund IV |
2021-01-20 |
| Neurent Medical–Fountain Healthcare Partners: investment, 202101 financing round Series B totalling €21m incl existing + co-investor Fountain HP |
2021-01-20 |
| Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2 |
2021-01-20 |
| Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2 |
2021-01-20 |
| Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services |
2021-01-20 |
| ConserV Bioscience–Optimum Strategic Communications: public relations, 202101 service existent by Optimum |
2021-01-19 |
| ConserV Bioscience–United States (govt): coronavirus vaccine, 202101– collab developm broad spectrum coronvirus vaccine using NLP technology from LLNL |
2021-01-19 |
| CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion |
2021-01-19 |
| Merus–SEVERAL: investment, 202101 public offering $120m+$18m with 4.85m+727.3k common shares at $24.75/share |
2021-01-19 |
| Slate Bio–Epidarex Capital: investment, 202101 seed financing round totalling $1.75m incl lead investor Epidarex Capital |
2021-01-19 |
| Slate Bio–SEVERAL: investment, 202101 seed financing round $1.75m led by Epidarex Capital |
2021-01-19 |
| LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH |
2021-01-18 |
| LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF |
2021-01-18 |
| LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG |
2021-01-18 |
| LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG |
2021-01-18 |
| Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher |
2021-01-15 |
| NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital |
2021-01-14 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Sanofi–Biond Biologics: antibody cancer drug, 202101– license ww excl to BND-22 anti-IgG4 antibody $125m upfront + >$1b milestones + royalties |
2021-01-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI |
2021-01-11 |
| Immunocore–BlackRock: investment, 202101 financing round Series C totalling $75m incl funds + accounts managed by BlackRock |
2021-01-11 |
| Immunocore–SEVERAL: investment, 202101 financing round Series C $75m incl funds + accounts managed by BlackRock |
2021-01-11 |
| Immunocore–Wafra: credit, 202101– senior secured loan facility $100m from Oxford Finance LLC |
2021-01-11 |
| Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED |
2021-01-11 |
| Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag |
2021-01-11 |
| Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners |
2021-01-11 |
| Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners |
2021-01-11 |
| Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake |
2021-01-11 |
| Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
| Valo Health–Canada (govt): investment, 202101 financing round Series B totalling $190m incl lead investor PSP Investments |
2021-01-11 |
| Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments |
2021-01-11 |
| Valo Health–SEVERAL: investment, 202101 financing round Series B $190m led by PSP Investments |
2021-01-11 |
| Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2021-01-08 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| BioGeneration Ventures–BMS: investment, 202101 final closing of BGV IV totalling €140m incl investor BMS |
2021-01-07 |
| BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund |
2021-01-07 |
| BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
| BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension |
2021-01-07 |
| BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif |
2021-01-07 |
| BioGeneration Ventures–Lilly: investment, 202101 final closing of BGV IV totalling €140m incl investor Eli Lilly |
2021-01-07 |
| BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures |
2021-01-07 |
| BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| Oxford Immunotec–PerkinElmer: investment, 202101– acquisition $591m with $22/share in cash ANNOUNCED |
2021-01-07 |
| Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m |
2021-01-07 |
| Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp |
2021-01-06 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare |
2021-01-05 |
| Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare |
2021-01-05 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
